JPH0432054B2 - - Google Patents
Info
- Publication number
- JPH0432054B2 JPH0432054B2 JP58061666A JP6166683A JPH0432054B2 JP H0432054 B2 JPH0432054 B2 JP H0432054B2 JP 58061666 A JP58061666 A JP 58061666A JP 6166683 A JP6166683 A JP 6166683A JP H0432054 B2 JPH0432054 B2 JP H0432054B2
- Authority
- JP
- Japan
- Prior art keywords
- pancreatic
- months
- surgery
- dimethadione
- shadow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- JYJFNDQBESEHJQ-UHFFFAOYSA-N 5,5-dimethyloxazolidine-2,4-dione Chemical compound CC1(C)OC(=O)NC1=O JYJFNDQBESEHJQ-UHFFFAOYSA-N 0.000 claims description 24
- 229950004446 dimethadione Drugs 0.000 claims description 24
- IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 claims description 20
- 229960004453 trimethadione Drugs 0.000 claims description 20
- 102000016997 Lithostathine Human genes 0.000 claims description 17
- 108010014691 Lithostathine Proteins 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 239000004575 stone Substances 0.000 description 28
- 238000001356 surgical procedure Methods 0.000 description 27
- 210000000277 pancreatic duct Anatomy 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 14
- 230000002308 calcification Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 241000282472 Canis lupus familiaris Species 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 206010033649 Pancreatitis chronic Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 5
- 230000003187 abdominal effect Effects 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000009534 blood test Methods 0.000 description 4
- 230000002183 duodenal effect Effects 0.000 description 4
- 210000001819 pancreatic juice Anatomy 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000021055 solid food Nutrition 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000028572 Hereditary chronic pancreatitis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000000407 Pancreatic Cyst Diseases 0.000 description 1
- 206010048984 Pancreatic abscess Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 235000006089 Phaseolus angularis Nutrition 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 235000010711 Vigna angularis Nutrition 0.000 description 1
- 240000007098 Vigna angularis Species 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000000387 litholytic effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000013842 nitrous oxide Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58061666A JPS59186916A (ja) | 1983-04-06 | 1983-04-06 | 膵石症治療剤 |
| US06/575,897 US4517309A (en) | 1983-04-06 | 1984-02-01 | Method for the treatment of calcifying pancreatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58061666A JPS59186916A (ja) | 1983-04-06 | 1983-04-06 | 膵石症治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59186916A JPS59186916A (ja) | 1984-10-23 |
| JPH0432054B2 true JPH0432054B2 (OSRAM) | 1992-05-28 |
Family
ID=13177776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58061666A Granted JPS59186916A (ja) | 1983-04-06 | 1983-04-06 | 膵石症治療剤 |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US4517309A (OSRAM) |
| JP (1) | JPS59186916A (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4994025A (en) * | 1989-08-29 | 1991-02-19 | Baxter International Inc. | Method of dissolving cholesterol-rich calculi with short chain halogenated organic solvents and cosolvents |
| US7947285B2 (en) * | 2003-12-12 | 2011-05-24 | Fein Seymour H | Methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis |
| US7381698B2 (en) * | 2003-12-12 | 2008-06-03 | Chirhoclin, Inc. | Methods for treatment of acute pancreatitis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE756350A (fr) * | 1969-09-18 | 1971-03-18 | Basf Ag | Procede pour la preparation de 5-methylene-2, 4-oxazolidine-diones et composes ainsi obtenus |
| US4183960A (en) * | 1978-02-01 | 1980-01-15 | Exxon Research & Engineering Co. | Detoxification by means of the controlled, in vivo secretion triggered rupture of liquid membrane capsules |
| US4367234A (en) * | 1980-07-28 | 1983-01-04 | Pfizer Inc. | Hypoglycemic 5-substituted oxazolidine-2,4-diones |
-
1983
- 1983-04-06 JP JP58061666A patent/JPS59186916A/ja active Granted
-
1984
- 1984-02-01 US US06/575,897 patent/US4517309A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPS59186916A (ja) | 1984-10-23 |
| US4517309A (en) | 1985-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lyon et al. | Phycomycosis of the gastrointestinal tract. | |
| CN109069503A (zh) | 纳美芬(nalmefene)、纳曲酮(naltrexone)或其衍生物在治疗(非)酒精性脂肪肝炎(nash)或非酒精性脂肪性肝病(nafld)的应用 | |
| JP2002524513A (ja) | 持続痛の治療 | |
| CN107929718A (zh) | Glp‑1类似物及gc‑c受体激动剂组合物缓释制剂及其制备方法 | |
| CA2172624A1 (en) | Controlled release potassium dosage form | |
| Schäfer | The endocrine organs | |
| JP2005528430A5 (OSRAM) | ||
| Schiffrin et al. | Some factors concerned in the production of experimental ulceration of the Gl tract in cats | |
| JP2003531171A (ja) | 高脂血症関連疾患に対する組成物および治療 | |
| US20250262225A1 (en) | Composition for treatment of covid-19 comprising taurodeoxycholic acid or pharmaceutically acceptable salt thereof as active ingredient | |
| Krause et al. | Maxillomandibular brown tumor–a rare complication of chronic renal failure | |
| US5362756A (en) | Use of fedotozine in the treatment of functional states of intestinal obstructions | |
| RU2261098C2 (ru) | Перорально распадающаяся композиция, содержащая миртазапин | |
| JP2020522491A (ja) | 胆汁酸性下痢、小腸切除又は胆嚢除去及び短腸症候群に関連する下痢を治療するための方法及び組成物 | |
| JPH0432054B2 (OSRAM) | ||
| JP2008501683A (ja) | 腸洗浄方法 | |
| EP3409271B1 (en) | Local anesthetics to facilitate food intake and food retention | |
| Weis et al. | Gallstone dissolution with chenodeoxycholic acid: a clinical study | |
| US4650668A (en) | Composition for relieving toothache pain and other forms of intense pain | |
| EP1547587A1 (en) | Agent for reducing side effects of diclofenac | |
| JP4384435B2 (ja) | くしゃみ抑制組成物 | |
| JP6937065B1 (ja) | 間質性肺炎の治療剤 | |
| Erlinger et al. | Effects of octreotide on biliary lipid composition and occurrence of cholesterol crystals in patients with acromegaly: A prospective study | |
| CN112870382A (zh) | 阿拉伯糖和硅油类消泡剂联合用于肠道准备 | |
| Huddy et al. | Hyperbaric oxygen as a treatment for malabsorption in a radiation-damaged short bowel |